European clot management device market to reach $200m by 2016: MRG
According to the report, the most significant growth in the European clot management device market through 2016 will occur in mechanical thrombectomy procedures.
Percutaneous thrombectomy devices, particularly mechanical thrombectomy devices, will grow from a relatively small base. These devices fill a previously unmet medical need in the percutaneous management of clots in the arteriovenous (AV) access, peripheral artery, venous and coronary indications.
Since physicians generally choose brands based on clinical evidence, companies seeking to enter this active market are focusing on gathering clinical data to prove the efficacy and safety of their devices. A number of randomized trials are underway, including ATTRACT and TAPAS II.
So far, only the German health system has approved reimbursement for these devices. As a result, Germany makes up more than half the total market. If, as expected, France approves reimbursement for mechanical thrombectomy in the peripheral vessels, this will lead to further growth in the segment by 2016.
The venous indication will see a 17 percent average annual growth and the peripheral artery indication a 12 percent average annual growth through 2016, said MRG. The growth in these two indications will drive the overall market. Although mechanical thrombectomy procedures are only a quarter of overall thrombectomies, the high average selling price of the devices means they make up more than half of total market value.
â€œMechanical thrombectomy is an active market in Europe, and new competitors are being attracted by its growth potential,â€ said MRG analyst Fareed Hameed. â€œWeâ€™ve seen a number of new devices since 2009, including Thromcat XT from Spectranetics as well as Rotarex S and Aspirex S from Straub Medical. In granting Class III CE Mark, the indications treatable by the Straub devices were expanded to include venous use, which should have a particularly big effect in Germany.â€
The research firm claims that Straub Medical and MEDRAD Interventional are currently the largest competitors in the European mechanical thrombectomy market, with the rest split between Arrow International (a Teleflex Medical company), Spectranetics and several smaller competitors.
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.